KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE)
KBIO
KBIO was delisted on the 16th of December, 2015.
36 hedge funds and large institutions have $28.7M invested in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) in 2014 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 5 reducing their positions, and 6 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 5
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
14% more capital invested
Capital invested by funds: $25.1M → $28.7M (+$3.63M)
3% more funds holding
Funds holding: 35 → 36 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$246K |
| 2 |
SIM
Spark Investment Management
New York
|
+$189K |
| 3 |
UBS AM
Chicago,
Illinois
|
+$144K |
| 4 |
Morgan Stanley
New York
|
+$139K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$1.41M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$78K |
| 3 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
-$35K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$23.2K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$21K |
KBIO Hedge Fund Activity: Q4 2014 in Review
36 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) for Q4 2014, worth a combined $28.7M — up 14% from $25.1M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new KBIO positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $246K. The largest seller was Deerfield Management, cutting an estimated $1.41M.
- 36 institutional investors held KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) (KBIO) as of Q4 2014, up from 35 in Q3 2014.
- Funds reported $28.7M of KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) stock for Q4 2014, up 14% quarter-over-quarter.
- 8 funds opened new KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) positions in Q4 2014 and 6 closed out, a net change of +2 holders.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) buyer in Q4 2014 was Renaissance Technologies, an estimated $246K added.
- The largest KALOBIOS PHARMACEUTICALS INC COM STK NEW (DE) seller in Q4 2014 was Deerfield Management, an estimated $1.41M sold.
Based on aggregated 13F filings for Q4 2014.